Jim Cornall
Base to Base Biotech
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.
Be sure to visit the podcast's website and support the creator: www.deeptechdigest.com
Author
Jim Cornall
Category
Podcast website
Latest episode
Nov 20, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Base to Base biotech podcast 60: Delivery method reduces prostate cancer tumour size 22.05.2026 24:43
This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster. Alessa Therapeutics Alessa Therapeutics recently announced positive preliminary phase 1 safety and efficacy data for its prostate cancer treatment Enolen. This was the first study to demonstrate that the FDA-approved prostate cancer compound enzalutamide can be safely a...
Base to Base biotech podcast 59: DIA helping biotech thrive, and Gorlin syndrome 15.05.2026 1:05:07
This week, we have a conversation with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza Bokhari. Times: 02:53 Medicus Pharma 29:13 DIA DIA DIA (Drug Information Association) is a global organisation that assists life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the issu...
Base to Base biotech podcast 58: Congenital myotonic dystrophy 08.05.2026 44:59
This week, we have a conversation with congenital myotonic dystrophy patient advocacy consultant Lisa Harvey-Duren, who was the founding Myotonic Dystrophy Foundation executive director in 2008, and Michael Snape, CEO and CSO of AMO Pharma, which is developing a treatment for the disease. AMO Pharma AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance...
Base to Base biotech podcast 57: Keeping drugs cool, and treatment resistant depression 01.05.2026 46:21
This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher, CEO of FundaMental Pharma, about treatment resistant depression. Times: 02:37 FundaMental Pharma 23:56 Lifeina FundaMental FundaMental Pharma is a preclinical biopharmaceutical company focused on developing new treatments for treatment‑resistant depression (TRD). The company’s p...
Base to Base biotech podcast 56: GRIN genes and relapsing MS 24.04.2026 1:03:28
This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic. Times: 02:54 Immunic 24:04 Neurvati Neurosciences/GRIN Therapeutics GRIN Therapeutics GRIN Therapeutics Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringin...
Base to Base biotech podcast 55: Beating transplant challenges and a circular supply chain 17.04.2026 1:02:37
This week, our conversations are with Steve Perrin, president and CSO of Eledon Pharmaceuticals, and Jason Bock, CEO and co-founder of CTMC. Times: 03:18 CTMC 35:46 Eledon Pharmaceuticals CTMC CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change in real time without charge ups and allowing for better control...
Base to Base biotech podcast 54: Parkinson’s disease and peptides 10.04.2026 40:43
This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje Willuweit, director preclinical development of Priavoid, and Karsten Eastman, CEO and co-founder of Sethera Therapeutics, about the company’s work on peptides. Times: 02:52 Sethera Therapeutics 22:35 Priavoid Priavoid Priavoid , a company advancing novel disease-modifying approaches for n...
Base to Base biotech podcast 53: Diagnosing autism and improving transplant outcomes 03.04.2026 1:00:43
On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO of LinusBio, on its test that can rule out if someone has autism, and we talk to Thomas Kledal, CEO of Synklino, about improving kidney transplantation outcomes through better cytomegalovirus (CMV) prevention. Times: 03:18 LinusBio 35:43 Synklino LinusBio LinusBio has expanded access to its ClearS...
Base to Base biotech podcast 52: Ketamine for depression, and a new company in the kidney disease space 27.03.2026 1:04:36
On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine and treatment-resistant depression, and with Krishna Polu, CEO, president and co-founder of new kidney health biotech company R1 Therapeutics. Times: 03:57 HMNC Brain Health 29:47 R1 Therapeutics HMNC Brain Health HMNC Brain Health is a Munich-based clinical-stage biopharma company...
Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease 20.03.2026 1:03:51
On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma...
Base to Base biotech podcast 50: Drugs for kidney transplants, glycans, and drug delivery 13.03.2026 1:11:50
As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was yesterday, we’ve been able to squeeze them both in. The conversations this week are with Hansa Biopharma CEO Renée Aguiar-Lucander, about imlifidase for kidney transplant patients; Kyron.bio CEO Emilia McLaughlin, about glycosylation; and hydrogel-based drug delivery solutions company AmacaTh...
Base to Base biotech podcast 49: Gene therapy for kidney disease, and using AI to transform diagnostics 06.03.2026 51:32
This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics. Times: 03:34 Purespring 24:11 Panakeia Technologies Purespring Therapeutics Purespring is a precision nephrolo...
Base to Base biotech podcast 48: GPCRs and beating neurodegenerative diseases 27.02.2026 52:47
The conversations on this week’s podcast are with CEO of Merz Therapeutics, Stefan König, about a variety of neurodegenerative conditions and a botulinum neurotoxin, and with CEO of Kainova Therapeutics, Sean MacDonald, about – among other things – G-protein coupled receptors, or GPCRs. Times: 03:21 Merz Therapeutics 30:34 Kainova Therapeutics Kainova Therapeutics Kainova Therapeutics is a clinica...
Base to Base biotech podcast 47: Accurate prostate cancer diagnosis and ocular gene therapy 20.02.2026 1:01:01
The conversations on this week’s podcast focus on a rapid and accurate prostate cancer diagnostic test, with Valley Diagnostics’ CEO Dave Taylor; and on gene therapy for retinal disease, with Lance Baldo, CEO of Beacon Therapeutics. Times: 03:12 Beacon Therapeutics 27:38 Valley Diagnostics Valley Diagnostics Valley Diagnostics is a Welsh company developing next‑generation lateral flow diagnostic t...
Base to Base biotech podcast 46: Endometriosis and closing care gaps 13.02.2026 48:02
The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO María Teresa Pérez Zaballos. Times: 03:09 Pangaea Data 23:43 endogene.bio Endogene.bio endogene.bio is a precision medicine company based in France developing a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health. The co...
Base to Base biotech podcast 45: Chronic pain, urology, Affibody molecules and radioligand therapy 06.02.2026 45:23
This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained Therapeutics. Times: 03:47 Affibody 23:28 Sustained Therapeutics Sustained Therapeutics A spin-out from the University of British Columbia in Canada, Sustained Therapeutics utilises a proprietary polymer gel technology to develop locally injected, long-acting medications. The platfo...
Base to Base biotech podcast 44: Treating breast cancer and how a CDMO and immun0-oncology company collaborate 30.01.2026 47:04
This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative breast cancer. We also have a conversation with Erik Manting, CEO of immunotherapy company Mendus, and Janet Hoogstraate, CEO of the CDMO helping them, North X Biologics. Times: 03:56 Pan Cancer T 20:23 Mendus/NorthX Biologics Mendus Mendus is a Swedish–Dutch immuno-oncology company developing...
Base to Base biotech podcast 43: Natural killer cell therapy and attacking tumours 23.01.2026 50:27
This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin. Times: 04:12 Artiva Biotherapeutics 21:30 Avacta Therapeutics Artiva Biotherapeutics Artiva Biotherapeutics is a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) ce...
Base to Base biotech podcast 42: Treating blood cancers, Scottish Brain Sciences and One BioHub Aberdeen, and is speech the new blood? 16.01.2026 1:16:16
This week, three interviews, and five guests. We have conversations with Ulrik Tirsted Zeuthen, CEO, and Katarina Cantell, founder/CSO of Adalyon; Nisit Khandelwal, co-founder/CEO, Cycuria Therapeutics; and Craig Ritchie, founder/CEO of Scottish Brain Sciences and Deborah O’Neil, CEO/CSO of NovaBiotics as well as chair of the Life Sciences board of Opportunity Northeast, which runs ONE BioHub, and...
Base to Base biotech podcast 41: Eyes, mitochondria and a growing hub 09.01.2026 53:30
This week, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we have a conversation about mitochondria, with the CEO of Vandria, Klaus Dugi, and there’s also a short discussion about GoCo Health Innovation City in Gothenburg, Sweden, with Moa Dicksdotter, Partnership and Ecosystem. Times: 02:35 Vandria 20:03 GoCo Health Innovation City 25:54 Oculis Looking to the eyes Oculis is a Sw...
Base to Base biotech podcast 40: Anchored immunotherapy, and healing the skin 19.12.2025 1:09:32
This week, we’re talking about skin and wounds, with Ned Swanson, president and chief medical officer at PolarityBio, and Nikolai Sopko, chief operating officer, chief scientific officer and director at PolarityBio; and we discuss anchored immunotherapy with Howard Kaufman, CEO of Ankyra Therapeutics. 04:03 Ankyra Therapeutics 34:31 PolarityBio Anchored immunotherapies Ankyra Therapeutics , based...
Base to Base biotech podcast 39: Gene therapy for eye problems, GAIA, and separation science 12.12.2025 1:06:20
This week, we have conversations with Jakob Andersson, vice president of engineering at Anaphora and founder and chairman of GAIA; Coave Therapeutics’ CEO Rodolphe Clerval; and MOBILion Systems’ CEO, Melissa Sherman. Times: 03:13 Coave Therapeutics 24:43 GAIA Conference 36:55 MOBILion Systems Genetic medicine for ophthalmology Coave Therapeutics is a Paris‑based biotechnology company focused on de...
Base to Base biotech podcast 38: Obesity, life sciences in the Netherlands, and killing cancer cells 05.12.2025 1:19:02
This week, we have conversations with Sjanna Bosma, international relations officer at Health Holland; Mark Bagnall, CEO of Phenomix; and PDS Biotechnology CEO Frank Bedu-Addo. 04:17 Phenomix 32:53 Health Holland 44:02 PDS Biotechnology Phenomix takes on obesity Phenomix Sciences is a biotechnology company focused on precision obesity medicine. The firm has developed the MyPhenome test, a saliva‑b...
Base to Base biotech podcast 37: Life Sciences in Flanders, AI and drug discovery, and healthcare investment 28.11.2025 1:04:59
This week, we have conversations with Jérôme Van Biervliet, chair of the board of Flanders life sciences body Biovia and managing director at VIB; Sylvain Sachot, partner at Asabys Partners; and Jonas Béal, head of science strategy, R&D, at Owkin. 03:32 Owkin 27:42 Biovia/VIB 38:06 Asabys Partners Biovia/VIB Biovia has emerged as a new health innovation cluster in the Belgian region of Flander...
Base to Base biotech podcast 36: Life science in Gothenburg, Charcot-Marie-Tooth disease and Ultrasound AI 21.11.2025 1:17:17
This week, we have conversations with Robert Bunn, founder and president of Ultrasound AI; Laura MacNeill, CEO of the Charcot Marie Tooth Research Foundation; and Iris Örhn, investment advisor at Business Region Göteborg. 03:00 Ultrasound AI 30:19 Business Region Gothenburg 39:35 CMTRF Business Region Gothenburg Business Region Gothenburg (BRG) is the regional development agency for western Sweden...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.